Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial

- Loo, Colleen, Glozier, Nick, Alonzo, Angelo, Dong, Vanessa, Martin, Donel, Nikolin, Stevan, Mitchell, Philip B., Berk, Michael, Carter, Gregory, Hackett, Maree, Leyden, John, Hood, Sean, Barton, David, Somogyi, Andrew A., Lapidus, K, Stratton, E, Gainsford, K, Garg, D, Thornton, NLR, Fourrier, C, Richardson, K, Rozakis, D, Scaria, A, Baune, Bernhard T., Mihalopoulos, C, Chatterton, ML, McDonald, WM, Boyce, P, Holtzheimer, PE, Kozel, FA, Riva-Posse, P, Rodgers, A, Mills, Natalie T., Fitzgerald, Paul, Glue, Paul, Sarma, Shanthi, Galvez-Ortiz, Veronica, Hadzi-Pavlovic, Dusan

Development of the Ketamine Side Effect Tool (KSET)

- Short, Brooke, Dong, Vanessa, Schoevers, Robert, Fraguas, Renerio, Glue, Paul, Fam, Johnson, McShane, Rupert, Loo, Colleen K., Gálvez, Verònica, Vulovic, Vedran, Martin, Donel, Bayes, Adam J., Zarate, Carlos A., Murrough, James W., McLoughlin, Declan M., Riva-Posse, Patricio